Advertisement
MASI vs PACB
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MASI is a Hold and PACB is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MASI’s FA Score shows that 1 FA rating(s) are green whilePACB’s FA Score has 0 green FA rating(s).
- MASI’s FA Score: 1 green, 4 red.
- PACB’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MASI’s TA Score shows that 5 TA indicator(s) are bullish while PACB’s TA Score has 4 bullish TA indicator(s).
- MASI’s TA Score: 5 bullish, 6 bearish.
- PACB’s TA Score: 4 bullish, 4 bearish.
Price Growth
MASI (@Medical Specialties) experienced а +6.57% price change this week, while PACB (@Medical Specialties) price change was +12.41% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +3.05%. For the same industry, the average monthly price growth was +4.97%, and the average quarterly price growth was -2.20%.
Reported Earning Dates
MASI is expected to report earnings on Nov 11, 2025.
PACB is expected to report earnings on Nov 10, 2025.
Industries' Descriptions
@Medical Specialties (+3.05% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| MASI | PACB | MASI / PACB | |
| Capitalization | 7.66B | 977M | 784% |
| EBITDA | 237M | -277.28M | -85% |
| Gain YTD | -0.411 | -15.847 | 3% |
| P/E Ratio | 95.93 | N/A | - |
| Revenue | 2.05B | 201M | 1,019% |
| Total Cash | 163M | 631M | 26% |
| Total Debt | 970M | 934M | 104% |
MASI | PACB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 61 | 82 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 100 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 99 | |
PRICE GROWTH RATING 1..100 | 55 | 43 | |
P/E GROWTH RATING 1..100 | 17 | 80 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MASI's Valuation (90) in the Medical Specialties industry is in the same range as PACB (100) in the Biotechnology industry. This means that MASI’s stock grew similarly to PACB’s over the last 12 months.
MASI's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as PACB (100) in the Biotechnology industry. This means that MASI’s stock grew similarly to PACB’s over the last 12 months.
MASI's SMR Rating (96) in the Medical Specialties industry is in the same range as PACB (99) in the Biotechnology industry. This means that MASI’s stock grew similarly to PACB’s over the last 12 months.
PACB's Price Growth Rating (43) in the Biotechnology industry is in the same range as MASI (55) in the Medical Specialties industry. This means that PACB’s stock grew similarly to MASI’s over the last 12 months.
MASI's P/E Growth Rating (17) in the Medical Specialties industry is somewhat better than the same rating for PACB (80) in the Biotechnology industry. This means that MASI’s stock grew somewhat faster than PACB’s over the last 12 months.
| MASI | PACB | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 72% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 71% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 67% | 1 day ago 83% |
| MACD ODDS (%) | 1 day ago 77% | 1 day ago 82% |
| TrendWeek ODDS (%) | 1 day ago 70% | 1 day ago 84% |
| TrendMonth ODDS (%) | 1 day ago 77% | 1 day ago 84% |
| Advances ODDS (%) | 4 days ago 70% | 4 days ago 86% |
| Declines ODDS (%) | 9 days ago 66% | 9 days ago 89% |
| BollingerBands ODDS (%) | 1 day ago 52% | 1 day ago 83% |
| Aroon ODDS (%) | 1 day ago 72% | 1 day ago 87% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| OBIOX | 23.46 | N/A | N/A |
| Oberweis International Opps Inv | |||
| FIDPX | 10.78 | N/A | N/A |
| Federated Hermes Intl Dividend Strategy | |||
| LVORX | 17.51 | N/A | N/A |
| Lord Abbett Value Opportunities R3 | |||
| PMEGX | 62.15 | N/A | N/A |
| T. Rowe Price Instl Mid-Cap Equity Gr | |||
| CEUFX | 60.41 | -0.32 | -0.53% |
| American Funds EUPAC 529-F-1 | |||
MASI and
Correlation & Price change
A.I.dvisor indicates that over the last year, MASI has been loosely correlated with INSP. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if MASI jumps, then INSP could also see price increases.
| Ticker / NAME | Correlation To MASI | 1D Price Change % | ||
|---|---|---|---|---|
| MASI | 100% | +2.01% | ||
| INSP - MASI | 48% Loosely correlated | +0.17% | ||
| ISRG - MASI | 46% Loosely correlated | +1.48% | ||
| VCYT - MASI | 46% Loosely correlated | +7.04% | ||
| ALGN - MASI | 44% Loosely correlated | +1.67% | ||
| BSX - MASI | 44% Loosely correlated | -0.07% | ||
More | ||||
PACB and
Correlation & Price change
A.I.dvisor indicates that over the last year, PACB has been loosely correlated with MASI. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if PACB jumps, then MASI could also see price increases.
| Ticker / NAME | Correlation To PACB | 1D Price Change % | ||
|---|---|---|---|---|
| PACB | 100% | N/A | ||
| MASI - PACB | 58% Loosely correlated | +2.01% | ||
| ILMN - PACB | 48% Loosely correlated | +1.54% | ||
| LAB - PACB | 46% Loosely correlated | -4.76% | ||
| AZTA - PACB | 45% Loosely correlated | +1.38% | ||
| CERS - PACB | 44% Loosely correlated | +2.21% | ||
More | ||||